Amoy Diagnostic Company

Amoy Diagnostics Co., Ltd. (AmoyDx) focuses on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS and Super-ARMS technologies, AmoyDx has a market-leading portfolio of molecular diagnostic kits including but not limited to EGFR, RAS, ALK, BRAF, PIK3CA and ROS1 testing kits, which were firstly approved by CFDA and CE certified. In European EMQN and Chinese PQCC quality control programs, AmoyDx is the NO.1 testing kit supplier for some years and always achieves the highest accuracy rate. Nowadays AmoyDx serves an extensive domestic and international oncology network reaching over 300 hospitals in China and 50 countries all over the world. Every year hundreds of thousands of cancer patients benefit from AmoyDx products.

Investors

Total Funding: $4.4M
Headquarters: China
Funding Status: IPO
Employee Number: 251-500
Estimated Revenue: $10M to $50M
Last Funding Type: Series B
Technology: diagnostics
Investor Type: For Profit
Last Funding Date: 2015-01-01
Investors Number: 1
Founded Date: 39448
Industry: Biotechnology, Health Care, Health Diagnostics, Medical
Register and Claim Ownership